MARA Holdings
MARA
MicroStrategy
MSTR
Coinbase
COIN
Tesla
TSLA
Amazon
AMZN
US Stock MarketDetailed Quotes
VINC Vincerx Pharma
- 0.152
- +0.012+8.71%
Close Jan 17 16:00 ET
- 0.152
- 0.000-0.20%
Post 19:57 ET
5.55MMarket Cap-0.18P/E (TTM)
0.156High0.142Low2.71MVolume0.155Open0.140Pre Close402.50KTurnover8.90%Turnover RatioLossP/E (Static)36.47MShares9.37252wk High0.61P/B4.64MFloat Cap0.14052wk Low--Dividend TTM30.46MShs Float26.750Historical High--Div YieldTTM10.28%Amplitude0.140Historical Low0.148Avg Price1Lot Size
About Vincerx Pharma Company
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Company Profile
SymbolVINC
Company NameVincerx Pharma
Listing DateMay 27, 2020
Founded2018
CEODr. Raquel E. Izumi, PhD
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address260 Sheridan Avenue,Suite 400
CityPalo Alto
ProvinceCalifornia
CountryUnited States of America
Zip Code94306
Phone1-650-800-6676
Websitehttp://vincerx.com
Company Executives
- Name
- Position
- Salary
- Dr. Raquel E. Izumi, PhD
- Director and Acting Chief Executive Officer
- 668.96K
- Kevin Haas
- Acting Chief Financial Officer
- --
- Tom C. Thomas
- General Counsel and Chief Legal Officer
- --
- Dr. Ahmed M. Hamdy, M.D.
- Chairman of the Board
- 734.95K
- Ruth E. Stevens
- Independent Director
- 47.89K
- Dr. Brian J. Druker, M.D.
- Independent Director
- 47.89K
- Francisco D. Salva
- Independent Director
- 69.14K
- Dr. Laura I. Bushnell, PhD
- Independent Director
- 52.89K
- Dr. John H. Lee, M.D.
- Independent Director
- 47.89K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.